Patents by Inventor Mathias Norrman

Mathias Norrman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141011
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Publication number: 20240067944
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 29, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • Publication number: 20230192801
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Applicants: Novo Nordisk A/S, Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Patent number: 11649269
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: May 16, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • Patent number: 11498951
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: November 15, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Publication number: 20220202909
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 30, 2022
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
  • Patent number: 11352406
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 7, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Anthony Murray, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Publication number: 20220009989
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 13, 2022
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • Publication number: 20210179685
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 17, 2021
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen
  • Publication number: 20200384088
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Application
    Filed: August 4, 2020
    Publication date: December 10, 2020
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
  • Publication number: 20200283493
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: March 25, 2020
    Publication date: September 10, 2020
    Inventors: Peter Madsen, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Patent number: 10596231
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: March 24, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
  • Publication number: 20190183979
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Application
    Filed: February 20, 2019
    Publication date: June 20, 2019
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
  • Patent number: 10265385
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analog, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 23, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
  • Publication number: 20190010206
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: August 24, 2016
    Publication date: January 10, 2019
    Inventors: Peter Madsen, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Publication number: 20180303908
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Application
    Filed: June 29, 2018
    Publication date: October 25, 2018
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
  • Publication number: 20180305431
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: August 24, 2016
    Publication date: October 25, 2018
    Inventors: Peter Madsen, Anthony Murray, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Publication number: 20180169190
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Application
    Filed: December 15, 2017
    Publication date: June 21, 2018
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen